Actively Recruiting
EEG and Behavioral Correlates of Temporal Prediction in the Tactile Modality in Schizophrenia
Led by Centre Psychothérapique de Nancy · Updated on 2026-03-25
68
Participants Needed
1
Research Sites
233 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Patients with schizophrenia have disturbances in their sense of self, particularly their bodily self. Disorders of the sense of self are central to schizophrenia and are of interest because they are thought to be present prior to the development of the disorder, when only a few attenuated symptoms signal a risk of developing psychosis. Finding markers related to the sense of self would make it possible to predict which subjects, among those with minimal psychotic symptoms, will develop psychosis, and thus to better adapt management. Disturbances in the experience of the passage of time that accompany disturbances in the sense of self have been described particularly in subjects at risk of developing psychosis, and would predict the onset of the pathology. However, as with alterations in the sense of self, it can be difficult to get patients to describe their disturbances in the experience of time, and objective measures are required to facilitate detection of these disturbances. In the present protocol an objective measure of temporal perception mechanisms will be tested in relation to the sense of self. The tests used in the protocol assess subjects' abilities to benefit from the passage of time and to use these abilities to predict and prepare for the occurrence of an event. The investigators have previously shown that patients with impaired bodily sense of self do not benefit from the passage of time to prepare themselves to process information in the future. The present protocol is aimed at developing a measure more sensitive to the patients' disorders by adding tactile measures.
CONDITIONS
Official Title
EEG and Behavioral Correlates of Temporal Prediction in the Tactile Modality in Schizophrenia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or Female
- Age between 18 and 60 years inclusive
- Signed consent form
- Enrolled in or beneficiary of a social security plan
You will not qualify if you...
- Psychoactive substance use disorders as defined by DSM-V
- Use of benzodiazepines within 5 half-lives prior to inclusion
- Cannabis use in the 2 months prior to inclusion (verified by urine test)
- Use of hallucinogenic substances within 5 half-lives prior to inclusion
- Neurological pathology or lasting effects
- Attention deficit hyperactivity disorder (ADHD)
- Borderline personality disorder
- Disabling sensory disorders
- Person deprived of liberty or under court protection
- Pregnant, parturient, or nursing women
- Currently excluded from another clinical study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Anne GIERSCH
Strasbourg, France
Actively Recruiting
Research Team
A
Anne GIERSCH, MD PhD
CONTACT
N
Naoual MELLOUKI BENDIM'RED, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here